The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation
Open accessAbstract
Background— Experimental studies revealed proinflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin in patients with essential hypertension and microinflammation. Methods and Results— We measured a panel of vascular inflammation markers, including high-sensitivity C-reactive protein, and lipid levels during 12 weeks of therapy with olmesartan (n=100) or placebo (n=99) in a prospective double-blind multicenter study. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Blood pressure control was achieved with addition of hydrochlorothiazide. Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (−15.1%; P <0.05), high-sensitivity tumor necrosis factor-α (−8.9%; P <0.02), interleukin-6 (−14.0%; P <0.05), and monocyte chemotactic protein-1 (−6.5%; P <0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. After 12 weeks of therapy, high-sensitivity C-reactive protein (−21.1%; P <0.02), high-sensitivity tumor necrosis factor-α (−13.6%; P <0.01), and interleukin-6 (−18.0%; P <0.01) decreased further with olmesartan and pravastatin cotherapy, but treatment with pravastatin alone (ie, cotherapy with placebo) did not significantly alter inflammation markers. In contrast, addition of pravastatin led to a significant ( P <0.001) reduction in LDL cholesterol serum concentrations in the olmesartan and placebo treatment groups (−15.1% and −12.1%, respectively). Conclusions— Angiotensin II receptor blockade significantly reduces vascular microinflammation in patients with essential hypertension by as early as week 6 of therapy. This antiinflammatory action of angiotensin II receptor antagonists may contribute to their beneficial cardiovascular effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 2×
“В кардиологии наибольшее внимание уделяется вчСРБ — важному предиктору риска будущих ССС в различных клинических популяциях [2,7-11].”
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 1×
“Как предиктор ССР, вчСРБ превосходил целый ряд воспалительных и липидных маркеров при их непосредственном сравнении [12].”
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513 · cited 5×
“Ассоциация между СРБ и ССР может носить дозозависимый характер: у лиц с уровнями вчСРБ 1-3 мг/л риск расценивается как средний, а у лиц с концентрацией вчСРБ >3 мг/л — как высокий [2, 9].”
InfluentialDirect Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,641
Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Verma, S., Wang, C.-H., Li, S.-H., Dumont, A. S., Fedak, P. W. M., Badiwala, M. V., Dhillon, B., Weisel, R. D., Li, R.-K., Mickle, D. A. G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000029802.88087.5e · Cited by 1,054
C-Reactive Protein and the Risk of Developing Hypertension
Sesso, H. D. (2003) · JAMA · doi:10.1001/jama.290.22.2945 · Cited by 1,004
Venugopal, S. K., Devaraj, S., Yuhanna, I., Shaul, P., & Jialal, I. (2002) · Circulation · doi:10.1161/01.cir.0000033116.22237.f9 · Cited by 853
Pasceri, V., Chang, J., Willerson, J. T., & Yeh, E. T. H. (2001) · Circulation · doi:10.1161/01.cir.103.21.2531 · Cited by 831
Jialal, I., Stein, D., Balis, D., Grundy, S. M., Adams-Huet, B., & Devaraj, S. (2001) · Circulation · doi:10.1161/01.cir.103.15.1933 · Cited by 730
Roberts, W. L., Moulton, L., Law, T. C., Farrow, G., Cooper-Anderson, M., Savory, J., & Rifai, N. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.418 · Cited by 652
Verma, S., Li, S.-H., Badiwala, M. V., Weisel, R. D., Fedak, P. W. M., Li, R.-K., Dhillon, B., & Mickle, D. A. G. (2002) · Circulation · doi:10.1161/01.cir.0000015126.83143.b4 · Cited by 634
Vascular inflammation and the renin-angiotensin system
Brasier, A. R., Recinos, A., & Eledrisi, M. S. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000021412.56621.a2 · Cited by 586 · cited 2×
“Однако до настоящего времени не проводились крупные, контролируемые исследования, изучающие противовоспалительные эффекты блокаторов ангиотензиновых рецепторов (БРА) 1 типа, несмотря на хорошо известные провоспалительные свойства ангиотензина II (АТII) [19-21].”
Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women
Tchernof, A., Nolan, A., Sites, C. K., Ades, P. A., & Poehlman, E. T. (2002) · Circulation · doi:10.1161/hc0502.103331 · Cited by 541
C-reactive protein and the risk of developing hypertension
Sesso, H. D., Buring, J. E., Rifai, N., Blake, G. J., Gaziano, J. M., & Ridker, R. M. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.02.025 · Cited by 430
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 421
Coming of Age of C-Reactive Protein: Using Inflammation Markers in Cardiology
Yeh, E. T. H., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000053731.05365.5a · Cited by 403 · cited 4×
“В кардиологии наибольшее внимание уделяется вчСРБ — важному предиктору риска будущих ССС в различных клинических популяциях [2,7-11].”
InfluentialRidker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000058687.18516.14 · Cited by 390
Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier, P., Grunwald, G. K., Marcovina, S. M., & Eckel, R. H. (2002) · Circulation · doi:10.1161/01.cir.0000029743.68247.31 · Cited by 354
Impact of Infectious Burden on Extent and Long-Term Prognosis of Atherosclerosis
Espinola-Klein, C., Rupprecht, H. J., Blankenberg, S., Bickel, C., Kopp, H., Rippin, G., Victor, A., Hafner, G., Schlumberger, W., & Meyer, J. (2002) · Circulation · doi:10.1161/hc0102.101362 · Cited by 338
Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events
Blake, G. J., Rifai, N., Buring, J. E., & Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000104566.10178.af · Cited by 336
Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors
Saito, M., Ishimitsu, T., Minami, J., Ono, H., Ohrui, M., & Matsuoka, H. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00380-5 · Cited by 238
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients
Koh, K. K., Ahn, J. Y., Han, S. H., Kim, D. S., Jin, D. K., Kim, H. S., Shin, M.-S., Ahn, T. H., Choi, I. S., & Shin, E. K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00846-5 · Cited by 225
Monocyte Infiltration and Adhesion Molecules in a Rat Model of High Human Renin Hypertension
Mervaala, E. M. A., Müller, D. N., Park, J.-K., Schmidt, F., Löhn, M., Breu, V., Dragun, D., Ganten, D., Haller, H., & Luft, F. C. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.389 · Cited by 223
Self-citationDandona, P., Kumar, V., Aljada, A., Ghanim, H., Syed, T., Hofmayer, D., Mohanty, P., Tripathy, D., & Garg, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021836 · Cited by 207
Magyar, M. T., Szikszai, Z., Balla, J., Valikovics, A., Kappelmayer, J., Imre, S. G., Balla, G., Jeney, V., Csiba, L., & Bereczki, D. (2003) · Stroke · doi:10.1161/01.str.0000048845.83285.ac · Cited by 142
Khan, B. V., Navalkar, S., Khan, Q. A., Rahman, S. T., & Parthasarathy, S. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01615-1 · Cited by 72
Cited by
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Renin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 663
Is atrial fibrillation an inflammatory disorder?
Boos, C. J., Anderson, R. A., & Lip, G. Y. H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi645 · Cited by 552
Structural and Functional Remodeling of the Left Atrium
Casaclang-Verzosa, G., Gersh, B. J., & Tsang, T. S. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.026 · Cited by 529
Metadata
- Authors
- Fliser, D., Buchholz, K., & Haller, H.
- Venue
- Circulation
- Published
- 2004-08-31
- Volume
- 110
- Issue
- 9
- Pages
- 1103-1107
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2152043519
- Cited by
- 404
- References
- 36
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.